Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Hoosier Cancer Research Network
Eli Lilly and Company
Kivu Bioscience Inc.
Achieve Life Sciences
BicycleTx Limited
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
7 Hills Pharma, LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
Deciphera Pharmaceuticals, LLC
Revolution Medicines, Inc.
Memorial Sloan Kettering Cancer Center
Pfizer
Shanghai Junshi Bioscience Co., Ltd.
USWM, LLC (dba US WorldMeds)
AstraZeneca
Actuate Therapeutics Inc.
Conjupro Biotherapeutics, Inc.
NRG Oncology
Alterome Therapeutics, Inc.
Verastem, Inc.
IDEAYA Biosciences
National Institutes of Health Clinical Center (CC)
Pfizer
Incyte Corporation
Aulos Bioscience, Inc.
Assistance Publique - Hôpitaux de Paris
Memorial Sloan Kettering Cancer Center
Mirati Therapeutics Inc.
Eli Lilly and Company
Aptamer Sciences, Inc.
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
AstraZeneca
Eli Lilly and Company
National Cancer Institute (NCI)
GlaxoSmithKline
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Institut Paoli-Calmettes
Orano Med LLC
Conjupro Biotherapeutics, Inc.